Ardelyx Inc

ARDX remains in a Stage 4 decline with bearish medium-term bias confirmed by active lower highs and lower lows under down-sloping EMAs. Price trades below key EMAs and in oversold territory, and the recent bounce lacks conviction, offering no clear execution edge. Under our Speculative strategy’s high-selectivity framework, we will defer selling and trim into rallies near the dynamic EMA resistance zone, seeking explicit rejection signals rather than chasing further downside.

• ↑Total revenue grew 38% YoY to $93.4M; Ibsrella sales up 58%.
• ↑Cash balance of $238.1M supports R&D and commercial expansion.
• ↓Operating expenses could reach $520M in 2026, net loss $37.6M.